ClinicalTrials.gg
RecruitingNCT07000084GAIN-BCGUpdated Oct 2, 2026

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

A Phase 3 interventional study of BCG Solution and Biopsy of Bladder in Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 and Stage I Bladder Cancer AJCC v8, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 2, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms — 11 open to participants now, 16 under way, 3 of them phase 3. Gemcitabine · Non-Muscle Invasive Bladder Neoplasms.

Planned enrollment
2nd of 20
330 · median 70
Started
2025
with 3 others
Phase 3
3 of 20
2 open now
Primary completion
2028-06
later than 10 of 15 live
Registered
16th of 20
by date
Lead sponsor
1 of 20
Alliance for Clinical Trials in Oncology

Among the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 10 of the 15 other live ones, and was the 16th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

11 of the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, or all of them as a file.
02

Study summary

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare high-grade recurrence-free-survival between treated with gemcitabine with BCG (GemBCG) compared to those treated with BCG alone.

SECONDARY OBJECTIVES:

I. To compare the proportion of patients who remain high grade cancer free on initial post-treatment cystoscopic biopsies/transurethral resection of bladder tumor (TURBT) (week 13/month 3) between those treated with GemBCG compared to those treated with BCG alone.

II. To compare the 6-month (Week 25) complete response rate and the complete response durability between patients treated with GemBCG compared to those treated with BCG alone among patients with pre-treatment CIS.

III. To compare the time to recurrence of any-grade bladder cancer between patients treated with GemBCG compared those treated with BCG alone.

IV. To compare the progression-free-survival between patients treated with GemBCG compared to those treated with BCG alone.

V. To compare the cystectomy-free-survival between patients treated with GemBCG compared to those treated with BCG alone.

VI. To compare the proportion of patients free from BCG-unresponsive NMIBC between those treated with GemBCG compared to those treated with BCG alone.

VII. To determine the safety of and toxicity associated with GemBCG treatment relative to that of BCG treatment alone.

EXPLORATORY OBJECTIVE:

I. To collect tumor tissue/bladder biopsies, blood, and urine samples for biobanking that will enable future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive BCG intravesically over 2 hours once per week (QW) for 6 weeks. 2-6 weeks after completing endoscopic assessment, patients receive BCG over 2 hours QW for 3 weeks at month 3, 6 and 12 in the absence of disease progression or unacceptable toxicity. Patients undergo bladder biopsy, TURBT, cystoscopy, computed tomography (CT) scan/ magnetic resonance imaging (MRI) and blood and urine sample collection throughout the study.

ARM B: Patients receive gemcitabe intravesically over 1 hour twice weekly on weeks 1 and 10 and once weekly on weeks 4 and 7. Patients also receive BCG intravesically over 2 hours QW on weeks 2, 3, 6, 8 and 9. 2-6 weeks after completing endoscopic assessment, patients receive gemcitable intravesically over 1 hour on week 1 and BCG intravesically over 2 hours on week 2-4 at month 3, 6 and 12 in the absence of disease progression or unacceptable toxicity. Patients undergo bladder biopsy, TURBT, cystoscopy, CT scan/MRI and blood and urine sample collection throughout the study.

After completion of study treatment, patients are followed every 3 months for 2 years, then every 6 months for 3 years up to 5 years from randomization.

03

Conditions studied

  • Recurrent Non-Muscle Invasive Bladder Carcinoma
  • Stage 0a Bladder Cancer AJCC v8
  • Stage I Bladder Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Documentation of Disease: Histologic confirmation of urothelial carcinoma that is high grade Ta, high grade T1, or Tis (Tis/carcinoma in situ [CIS] only disease) within 120 days prior to randomization
  • Any component of neuroendocrine carcinoma (i.e., small cell or large cell) is not allowed. Other histologic subtypes/variant histologies are allowed so long as there is a predominantly urothelial component.

    * Note: Pure squamous cell carcinoma or pure adenocarcinoma without a urothelial component are not allowed

  • All visible papillary lesions must be macroscopically resected by TURBT within 90 days of randomization. (Residual CIS is permitted).

    * If the treating urologist did not perform the TURBT, the treating urologist must perform a cystoscopy within 45 days prior to randomization to confirm the absence of visible papillary disease

  • All patients with high grade T1 must undergo a restaging TURBT within 90 days of randomization. Patients who undergo a restaging TURBT that shows no residual cancer in the specimen are still eligible for trial based on prior TURBT
  • Patients must have BCG-Exposed non muscle invasive bladder carcinoma (NMIBC), defined as recurrent high grade NMIBC within 24 months of last BCG exposure but not meeting the definition of BCG unresponsive disease

    • Note: Up to 26 months from the last BCG instillation is allowed for the treating physician to perform a transurethral resection of bladder tumor (TURBT) so long as there is evidence/suspicion of recurrent disease (by positive cytology, imaging, or cystoscopy) within 24 months of last exposure to BCG.
    • Note: A patient who previously met the definition of BCG unresponsive NMIBC but no longer currently meets unresponsive criteria may still enroll in this trial so long as the treating urologist believes re-treatment with BCG is a reasonable treatment option for that patient.
    • BCG-exposed NMIBC criteria is defined as:

      • Any high grade NMIBC recurrence within 24 months of induction only BCG, or
      • A high grade papillary NMIBC (Ta/T1) recurrence between 6-24 months of last exposure to induction + maintenance BCG, or
      • A high-grade CIS (with or without Ta/T1 papillary disease) recurrence within 12-24 months of last exposure to induction + maintenance BCG.
    • Patient must not have BCG-unresponsive NMIBC, defined as:

      • Persistent or recurrent high-grade papillary NMIBC (Ta/T1) \< 6 months of "adequate" BCG, or
      • A high-grade CIS (with or without Ta/T1 papillary disease) recurrence \< 12 months of "adequate" BCG, or
      • A high grade T1 recurrence at the first 3-month assessment from induction BCG
      • "Adequate" BCG is defined as ≥5 of 6 doses of induction BCG therapy with either

        • ≥ 2 of 3 doses of maintenance BCG, or
        • ≥ 2 of planned 6 instillations of repeat induction BCG given within a 6 month time period
  • More than one prior induction course of BCG and/or prior maintenance BCG is allowed so long as the patient does not currently met the definition of BCG unresponsive disease
  • Prior treatment with any intravesical chemotherapy (both perioperative and induction course) for NMIBC is allowed, including gemcitabine either alone or in combination (ie. gemcitabine plus docetaxel) or gemcitabine delivered through a intravesical delivery system (ie. TAR-200)
  • Prior treatment with any systemic or intravesical agents for NMIBC is allowed, regardless of whether it is given either alone or in prior combination with BCG (ie. Prior treatment with pembrolizumab, other , nadofaragene firadenovec, nogapendekin alfa inbakicept, cretostimogene grenadenorepvec, etc. are all allowed)
  • Patients must not have a history of intolerance to BCG (ie needing to stop BCG induction or maintenance due to toxicity) or intolerance to any other intravesical therapies
  • Patients must not have compromised bladder function such that they are unlikely to tolerate further intravesical therapies
  • Patient must not have any prior history or current evidence of muscle-invasive (i.e., T2, T3, T4), locally advanced unresectable, or urothelial carcinoma as assessed on radiographic imaging obtained within 120 days prior to randomization.

    * The radiographic imaging includes a CT Scan or MRI of the abdomen/pelvis with intravenous contrast, with a CT or MRI urogram preferred. If a patient is unable to receive intravenous contrast due to renal function or allergy, then either a CT scan or MRI of the abdomen/pelvis without intravenous contrast is acceptable

  • Patients with a history of upper tract urothelial carcinoma are allowed so long as they had localized non-muscle invasive (Ta, T1, Tis) that has been definitively treated with surgery (nephroureterectomy or ureterectomy) with at least one post-treatment disease assessment imaging study that demonstrates no evidence of residual upper tract disease
  • Patients with a history of, or current evidence of, non-invasive (Ta/Tis) urothelial carcinoma of the prostatic urethra are eligible so long as a transurethral resection of prostate (TURP) is performed before enrollment and there is prostatic glandular tissue without evidence of lamina propria invasion or prostatic stromal invasion
  • -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • Age ≥ 18 years
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Not pregnant and not nursing, Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • has achieved menarche at some point
    • has not undergone a hysterectomy or bilateral oophorectomy
    • has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Active comparator
    Arm A (BCG)

    Patients receive BCG intravesically over 2 hours QW for 6 weeks. 2-6 weeks after completing endoscopic assessment, patients receive BCG over 2 hours QW for 3 weeks at month 3, 6 and 12 in the absence of disease progression or unacceptable toxicity. Patients undergo bladder biopsy, TURBT, cystoscopy, CT scan/MRI and blood and urine sample collection throughout the study.

    Biological: BCG Solution · Procedure: Biopsy of Bladder · Procedure: Cystoscopy · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection · Procedure: Transurethral Resection of Bladder Tumor

  • Experimental
    Arm B (BCG and gemcitabine)

    Patients receive gemcitabe intravesically over 1 hour twice weekly on weeks 1 and 10 and once weekly on weeks 4 and 7. Patients also receive BCG intravesically over 2 hours QW on weeks 2, 3, 6, 8 and 9. 2-6 weeks after completing endoscopic assessment, patients receive gemcitable intravesically over 1 hour on week 1 and BCG intravesically over 2 hours on week 2-4 at month 3, 6 and 12 in the absence of disease progression or unacceptable toxicity. Patients undergo bladder biopsy, TURBT, cystoscopy, CT scan/MRI and blood and urine sample collection throughout the study.

    Biological: BCG Solution · Procedure: Biopsy of Bladder · Procedure: Cystoscopy · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection · Procedure: Transurethral Resection of Bladder Tumor · Drug: Gemcitabine

Interventions

  • BiologicalBCG Solution

    Given intravesically

    Also known as: Bacillus Calmette Guerin Solution

  • ProcedureBiopsy of Bladder

    Undergo bladder biopsy

    Also known as: Bladder Biopsy

  • ProcedureCystoscopy

    Undergo cystoscopy

  • ProcedureComputed Tomography

    Undergo CT Scan

    Also known as: CAT Scan, CT Scan

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: MRI

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

  • ProcedureTransurethral Resection of Bladder Tumor

    Undergo TURBT

    Also known as: TURBT

  • Given intravesically

06

What researchers measure

Primary outcomes

  1. High Grade Recurrence-free survival (HG-RFS)

    HG-RFS will be calculated from randomization until the detection of a high-grade bladder cancer recurrence (biopsy proven intravesical recurrence or distant metastasis), cystectomy, or death, whichever occurs first. Patients who are alive and without documented high-grade recurrence will be censored at the time of last disease evaluation. HG-RFS will be compared between the two study arms using a stratified log-rank test. The treatment effect will be estimated with a hazard ratio (HR) and corresponding 95% confidence interval obtained from a stratified Cox model with treatment group (

    Time frame: Up to 5 years

Secondary outcomes

  1. High-grade cancer free at 3 months

    A patient will be classified as being cancer free if no high-grade bladder cancer is detected upon a cystoscopic biopsy (± transurethral resection of bladder tumor \[TURBT\]). This will be calculated as the number of patients who underwent cystoscopic biopsy with or without TURBT at 3 months and no high-grade cancer was detected, divided by the total number of patients.

    Time frame: at 3 months

  2. 6-month Complete Response

    Complete response rate will be determined among patients who had carcinoma in situ (CIS) at baseline. Patients will be classified as having a complete response at 6 months if there is no biopsy-proven high grade bladder cancer detected based on a cystoscopy and urinary cytology (± biopsy/TURBT). This will be calculated as the number of patients who had CIS at baseline and who had no evidence of disease at 6-months, divided by the total number of patients who had CIS at baseline. The proportion of patients who remain with a complete response will be compared between the two arms with a chi-square test or Fisher's exact test.

    Time frame: At 6 months

  3. Durability of Response

    o Durability of the response will be determined only in the patients who had CIS at baseline and had a complete response at 6 months. This will be measured as time from the 6-month evaluation until documented disease recurrence, censoring patients without disease recurrence at time of death or at last disease evaluation, whichever is last. The durability of response will be compared between the two treatment groups using a log-rank test, and Kaplan-Meier estimators will be used to determine the median durability.

    Time frame: Up to 5 years

  4. Recurrence-free survival

    Recurrence-free survival will be calculated as the time from randomization until the detection of any grade bladder cancer, censoring those without documented disease recurrence at time of last disease evaluation or death, whichever occurs last. This will be compared between the two treatment arms using a stratified log-rank test. An estimate of the outcome differences between the arms will be made with a HR and 95% confidence interval generated by a stratified Cox model.

    Time frame: Up to 5 years

  5. Progression-free survival

    Progression-free survival will be calculated as the time from randomization until disease progression, defined as development of muscle invasive disease (stage greater than or equal to T2), lymph node or distant metastasis, or death without documented disease progression. This will be compared between the two treatment arms using a stratified log-rank test. An estimate of the outcome differences between the arms will be made with a HR and 95% confidence interval generated by a stratified Cox model.

    Time frame: up to 5 years

  6. Cystectomy-free survival

    Cystectomy-free survival will be defined as the time from randomization until the patient undergoes a cystectomy, censoring patients without a cystectomy at last follow-up or death, whichever is last. This will be compared between the two treatment arms using a stratified log-rank test. An estimate of the outcome differences between the arms will be made with a HR and 95% confidence generated by a stratified Cox model.

    Time frame: up to 5 years

  7. • Bacille Calmette Guerin (BCG)-unresponsive non muscle invasive bladder cancer free survival

    BCG unresponsive NMIBC free survival will be defined as time from randomization until the patient develops BCG unresponsive NMIBC, defined as persistent or recurrent high-grade papillary NMIBC (Ta/T1) \<6 months of "adequate" BCG (≥5 of 6 plus an additional ≥2 doses of BCG) or CIS (with or without Ta/T1 papillary disease) recurrence \<12 months of "adequate" BCG (≥5 of 6 plus an additional ≥2 doses of BCG) or High Grade T1 at week 13 (month 3) assessment. Patients who do not develop BCG-unresponsive NMIBC will be censored at the time of their last follow-up or death, whichever is last. This will be compared between the two treatment arms using a stratified log-rank test. An estimate of the outcome differences between the arms will be made with a HR and 95% confidence interval generated by a stratified Cox model.

    Time frame: up to 5 years

  8. Rate of Grade 3+ Adverse Events

    o Adverse events will be collected and graded according to the NCI Common Terminology Criteria for Adverse Events version 5.0. The number (percent) of patients that experience each grade 3+ adverse event will be summarized by treatment arm. In addition, the number (percent) of patients that experience a grade 3+, grade 4+, and grade 5 adverse event will be summarized by treatment arm.

    Time frame: Up to 5 years

07

Study locations

60 of 60 sites recruiting
08

References and documents

Publications

  • Gaffney CD, Alam SM, Wald G, Sjoberg D, Eichholz J, Sarungbam J, D'Souza N, Lavery J, Hernandez C, Tomerlein M, Zagajeski P, Hildreth KW, Donat S, Smith R, Donahue T, Goh A, Bochner B, Al-Ahmadie H, Pietzak E. A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer. J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324. Online ahead of print. PubMed 42821609 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
May 31, 2025
StartActual
Jul 17, 2025
Primary completionEst.
Jun 5, 2028
CompletionEst.
Dec 5, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Renown Regional Medical Center · Reno, United States
  • Veterans Affairs New York Harbor Healthcare System-Manhattan Campus · New York, United States
Oct 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    2 sites added
    Show 2 added (2 United States)
    • Renown Regional Medical Center · Reno, United States
    • Veterans Affairs New York Harbor Healthcare System-Manhattan Campus · New York, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07000084
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jul 17, 2025
Primary completion
Jun 5, 2028 (estimated)
Completion
Dec 5, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Aishwarya Vijendran
Contact
guprotocols@alliancenctn.org
(773) 702-9171
Eugene Pietzak, MD
study chair · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion